Study guide
10.3 Metabolic Syndrome and Cardiometabolic Risk
AACN Cardiac Medicine Certification CMC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview and the CMC Test Plan
1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them
2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease
2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy
3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease
3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup
4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions
4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation
5 Chapter 5: Vascular Conditions and Vascular Interventions
5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications
6 Chapter 6: Shock States and Mechanical Circulatory Support
6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD
7 Chapter 7: Cardiac Procedures and Structural Heart Interventions
7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications
8 Chapter 8: Cardiovascular Pharmacology
8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure
9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary
9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients
10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral
10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients
11 Chapter 11: Monitoring and Diagnostics
11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography
12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions
12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease
10.3 Metabolic Syndrome and Cardiometabolic Risk
Key Takeaways Explain This Topic AI
Metabolic syndrome requires any 3 of 5: waist 102 cm/40 in or more in men and 88 cm/35 in or more in women, triglycerides 150 mg/dL or more, HDL below 40 (men) or 50 (women), BP 130/85 or higher, and fasting glucose 100 mg/dL or more - and drug therapy for a component counts as meeting it.
Insulin resistance and visceral adiposity produce small dense LDL, so non-HDL cholesterol and apolipoprotein B stratify risk better than LDL-C alone in these patients.
Pooled Cohort Equations risk bands are low below 5%, borderline 5-7.4%, intermediate 7.5-19.9%, and high 20% or more; coronary artery calcium refines the intermediate band, where a score of 0 supports deferring a statin and 100 or more supports starting one.
A 5-10% weight loss plus 150 minutes per week of moderate activity improves every component; the Diabetes Prevention Program achieved a 58% reduction in incident diabetes with 7% weight loss.
Semaglutide 2.4 mg weekly reduced major adverse cardiovascular events by about 20% in patients with obesity and established CVD without diabetes, and cardiac rehabilitation referral before discharge is the strongest driver of enrollment.
Last updated: August 2026
What Metabolic Syndrome Is, and the Exact Numbers
Metabolic syndrome is a clustering of interrelated cardiometabolic abnormalities that roughly doubles the risk of atherosclerotic cardiovascular disease (ASCVD) and increases the risk of incident type 2 diabetes about fivefold. It affects roughly one in three United States adults and more than half of adults over 60. On the CMC exam it appears as a risk-stratification and patient-education item: you are expected to recognize the cluster in a bedside chart, quantify the risk, and drive the discharge plan.
The harmonized definition (National Cholesterol Education Program ATP III as updated by AHA/NHLBI and the 2009 joint statement) requires any 3 of the following 5 criteria :
Criterion Threshold Counts if on treatment
Abdominal obesity (waist circumference) 40 inches / 102 cm or more in men; 35 inches / 88 cm or more in women Not applicable
- Triglycerides 150 mg/dL or more Yes - drug therapy for elevated triglycerides counts
- HDL cholesterol Below 40 mg/dL in men; below 50 mg/dL in women Yes - drug therapy for low HDL counts
- Blood pressure 130 mm Hg systolic or more, or 85 mm Hg diastolic or more Yes - antihypertensive therapy counts
- Fasting glucose 100 mg/dL or more Yes - drug therapy for hyperglycemia counts
Two traps live in this table. First, "on therapy" satisfies the criterion : a patient whose blood pressure is 118/70 on lisinopril still meets the blood-pressure criterion, and a patient with a triglyceride level of 96 mg/dL on fenofibrate still meets the triglyceride criterion. Second, the waist thresholds are population-specific . The International Diabetes Federation uses lower cut points for people of South Asian, Chinese, Japanese, and other Asian ancestry — 90 cm in men and 80 cm in women — so a normal-BMI South Asian patient can be centrally obese by any clinically meaningful standard while falling below the 102/88 cm values.
Measure the waist correctly: a horizontal tape at the top of the iliac crest, snug without compressing, read at the end of a normal expiration. A waist measured over a gown, at the umbilicus of a pendulous abdomen, or after a deep breath is not a usable data point.
Pathophysiology in one pass
Metabolic syndrome is driven by visceral adiposity and insulin resistance . Visceral adipose tissue is an endocrine organ that drains into the portal circulation. Its excess lipolysis floods the liver with free fatty acids, which worsens hepatic insulin resistance and drives overproduction of very-low-density lipoprotein. At the same time the adipose secretory profile shifts: adiponectin (insulin-sensitizing, anti-inflammatory) falls while leptin , tumor necrosis factor alpha, interleukin-6, and resistin rise. The consequences are the ones the cardiac nurse sees:
Atherogenic dyslipidemia : high triglycerides, low HDL, and a shift toward small dense LDL particles . LDL cholesterol may look unimpressive while particle number is high, which is why non-HDL cholesterol (total minus HDL, target generally 30 mg/dL above the LDL goal) and apolipoprotein B are better risk markers in this population than LDL-C alone.
Prothrombotic state : elevated plasminogen activator inhibitor-1 and fibrinogen, impaired fibrinolysis.
Pro-inflammatory state : elevated high-sensitivity C-reactive protein.
Vascular effects : endothelial dysfunction with reduced nitric oxide bioavailability, sympathetic activation, adipose-tissue renin-angiotensin-aldosterone activation, and sodium retention that make hypertension harder to control.
The conditions that travel with it
Metabolic dysfunction-associated steatotic liver disease (MASLD , formerly non-alcoholic fatty liver disease) — the hepatic manifestation of the same physiology, and an independent ASCVD risk marker.
Obstructive sleep apnea — screen with STOP-BANG; untreated OSA is a leading cause of resistant hypertension, nocturnal angina, and atrial fibrillation recurrence after cardioversion or ablation.
Polycystic ovary syndrome — insulin resistance in reproductive-age women, with its own long-term ASCVD risk.
Chronic kidney disease and albuminuria — a urine albumin-to-creatinine ratio above 30 mg/g is both a consequence and an independent risk multiplier.
Hyperuricemia and gout , erectile dysfunction (an early marker of endothelial disease), and heart failure with preserved ejection fraction.
Quantifying Risk
Do not stop at "the patient has metabolic syndrome." Quantify.
Pooled Cohort Equations estimate 10-year ASCVD risk in adults 40 to 75 without established disease: low below 5 percent, borderline 5 to 7.4 percent, intermediate 7.5 to 19.9 percent, high 20 percent or above . Intermediate risk is where the shared decision-making conversation lives.
PREVENT (Predicting Risk of cardiovascular disease EVENTs, AHA 2023) is the newer tool. It estimates 10-year and 30-year risk, starts at age 30, includes heart failure as an outcome, incorporates estimated glomerular filtration rate, and optionally urine albumin-to-creatinine ratio, hemoglobin A1c, and a social deprivation index. It generally produces lower absolute risk estimates than the Pooled Cohort Equations.
Coronary artery calcium (CAC) scoring is the best available risk refiner when the decision about statin therapy is genuinely uncertain at intermediate risk. A CAC of 0 supports deferring statin therapy in a patient without diabetes, without a strong family history, and who does not smoke ("the power of zero"). CAC 1 to 99 favors statin therapy, particularly at age 55 or older. CAC 100 or above, or at or above the 75th percentile for age, sex and ethnicity , supports statin initiation.
Risk enhancers that push a borderline or intermediate patient toward treatment: family history of premature ASCVD, persistent LDL-C 160 mg/dL or higher, chronic kidney disease, metabolic syndrome itself , chronic inflammatory disease, South Asian ancestry, history of preeclampsia or premature menopause, persistent triglycerides 175 mg/dL or higher, lipoprotein(a) 50 mg/dL or higher, apolipoprotein B 130 mg/dL or higher, ankle-brachial index below 0.9, and high-sensitivity C-reactive protein 2.0 mg/L or higher.
Managing the Cluster
There is no drug for "metabolic syndrome." You treat each component and you treat the adiposity that drives all five.
Lifestyle intervention with actual targets
Weight loss of 5 to 10 percent of body weight improves every component. In the Diabetes Prevention Program, a 7 percent weight loss with 150 minutes of activity per week reduced progression to type 2 diabetes by 58 percent — more than metformin did.
150 minutes per week of moderate-intensity aerobic activity (or 75 minutes vigorous), spread over most days, plus resistance training on 2 or more days per week . Breaking up prolonged sitting has independent benefit.
Dietary pattern over single nutrients : Mediterranean or DASH patterns, sodium below 2,300 mg daily with an ideal target of 1,500 mg for hypertension, minimal added sugar and sugar-sweetened beverages, replacement of saturated with unsaturated fat, and increased fiber.
Smoking cessation, alcohol limited to 2 drinks daily for men and 1 for women, and 7 to 9 hours of sleep with treatment of diagnosed sleep apnea.
Pharmacotherapy by component
Component First-line pharmacotherapy Cardiac notes
LDL / atherogenic dyslipidemia Moderate- or high-intensity statin; add ezetimibe, then a PCSK9 inhibitor or inclisiran Target at least 50% LDL-C reduction and LDL-C below 70 mg/dL in established ASCVD, below 55 mg/dL in very-high-risk patients
Triglycerides 150-499 mg/dL with ASCVD or diabetes Icosapent ethyl 2 g twice daily on top of a statin Reduced major adverse cardiovascular events by about 25% in REDUCE-IT; watch for atrial fibrillation and bleeding
Triglycerides above 500 mg/dL Fibrate or high-dose omega-3 Priority is pancreatitis prevention, not ASCVD reduction
Blood pressure Target below 130/80 mm Hg; ACE inhibitor or ARB preferred with diabetes or albuminuria Add a thiazide-like diuretic or dihydropyridine calcium channel blocker; spironolactone for resistant hypertension
Hyperglycemia Metformin; then SGLT2 inhibitor or GLP-1 receptor agonist based on comorbidity SGLT2 inhibitor if heart failure or CKD predominates; GLP-1 receptor agonist if ASCVD or weight predominates
Obesity pharmacotherapy and surgery
The obesity drugs are now cardiovascular drugs, and CMC candidates should know the headline outcome data:
Semaglutide 2.4 mg weekly reduced major adverse cardiovascular events by about 20 percent in patients with overweight or obesity and established cardiovascular disease without diabetes (SELECT), and improved symptoms and exercise capacity in obesity-related HFpEF (STEP-HFpEF).
Tirzepatide , a dual GIP and GLP-1 receptor agonist, produced weight loss of roughly 20 percent in SURMOUNT-1 and reduced heart-failure events while improving quality-of-life scores in obesity-related HFpEF (SUMMIT).
Nursing implications: dose escalation is slow and deliberate to limit nausea; delayed gastric emptying raises aspiration concern around sedation and intubation; injection technique, storage, and refill/cost barriers dominate adherence; and rapid weight loss requires reassessment of antihypertensive, diuretic, and insulin doses.
Metabolic and bariatric surgery is indicated at a BMI of 35 kg/m2 or more, or 30 or more with type 2 diabetes, and produces durable weight loss with reduced macrovascular events.
Cardiac rehabilitation is a class I recommendation after ACS, PCI, CABG, and in chronic HFrEF, and reduces cardiovascular mortality — yet only about a quarter of eligible patients ever enroll. Referral placed before discharge , with the first appointment scheduled, is the single most effective driver of enrollment and is squarely a nursing responsibility.
Health equity and the nurse's role
Cardiometabolic risk tracks with the social determinants of health: food insecurity and limited access to fresh food, neighborhoods without safe places to walk, shift work and sleep disruption, insurance status, medication cost (GLP-1 agonists in particular), transportation to cardiac rehabilitation, health literacy, and structural racism. PREVENT explicitly incorporates a social deprivation index because these factors change outcomes. Practical nursing actions: screen for food and medication insecurity in plain language, involve social work and pharmacy for assistance programs before discharge rather than after a refill fails, and check that rehabilitation is geographically and financially reachable.
Use motivational interviewing rather than instruction. Ask permission before giving information, use open questions, affirm, reflect, and summarize, elicit the patient's own reasons for change, and resist the "righting reflex" — correcting the patient generates resistance and argument rather than behavior change. Close with a teach-back confirmation, a reconciled medication list, follow-up within 7 days, and a written plan that names one or two concrete, measurable behaviors rather than "eat better and exercise more."